Recent Advances in Imaging for Diagnosis, Monitoring, and Prognosis of Psoriatic Arthritis
Angelo Fassio
Peter Matzneller
Luca Idolazzi- 1Rheumatology Unit, University of Verona, Verona, Italy
- 2Rheumatology Service, South Tyrolean Health Trust, Silandro Hospital, Silandro, Italy
Psoriatic arthritis (PsA) is an inflammatory condition characterized by a strong heterogeneity and multifaceted behavior. PsA manifests in two types—axial and peripheral—which may be present at the same time. Peripheral manifestations can be further divided into the articular (arthritis) and extra-articular (i.e., enthesitis and dactylitis) subgroups. In such a complex disease, imaging is often required to characterize the type of involvement and to evaluate the radiological damage and progression of PsA. In addition, imaging plays a pivotal role in clinical practice; that is, for axial involvement. Conventional radiology has been the main standard of reference for many years. However, in recent years, there has been growing interest in different imaging modalities, such as ultrasonography (US) and magnetic resonance imaging (MRI). All these techniques play a role in the diagnosis and follow-up of patients with PsA and cover all the types of the disease. US and MRI have good sensitivities and specificities for detecting synovitis, and this may be helpful for differential diagnosis with other musculoskeletal diseases and useful in the early or preclinical phases of the disease. However, US is not useful in the diagnosis of axial PsA. In addition, other modalities have been investigated in the field of PsA imaging. Computed tomography (CT), in particular, dual energy-CT and high-resolution peripheral CT (HRpQ-CT) might play an important role in the assessment of bone damage, erosions, and new bone formation. Regarding advanced functional imaging, FDG PET/CT is another interesting technique for exploring disease activity.
Introduction
Psoriatic arthritis (PsA) is characterized by a wide spectrum of features and can express itself as part of the psoriatic disease (1). Starting from the early phase of the disease, imaging plays a crucial role for diagnosis, prognosis, and management. The main types of PsA can be distinguished in the axial and peripheral regions, and they can be present alone or concurrently. Furthermore, peripheral PsA may involve joints as well as extra-articular structures, such as the entheses (2), and a concomitant inflammation of these can occur, such as in dactylitis (3). Patients with PsA often need a comprehensive evaluation that involves several imaging techniques. Clinicians should carefully choose proper imaging techniques in favor of achieving early diagnosis and, consequently, favorable clinical outcomes. This is especially true for axial involvement (4), for which under-diagnosis is still an issue (5). The definition of the type(s) and extension of the involvement is currently a challenging aspect of imaging in rheumatology because the different spondyloarthritides (SpA) forms have various clinical presentations (6, 7).
Given the heterogeneous nature of PsA, rheumatologists often face presentations of the disease that differ significantly between cases. Imaging can differentiate between PsA types as well as highlight differences to other SpA (i.e., ankylosing spondylitis).
The radiographic signs of structural axial damage in SpA typically involve erosive changes, followed by new bone formation and ankylosing alterations (8). The assessment of these changes is useful for both management and prognosis. In particular, disease activity is a strong determinant for the treatment choices of rheumatologists. Magnetic resonance (MRI) and ultrasonography (US) are helpful in the objective reflection of disease activity, and conventional radiography (XR) and especially computed tomography (CT) are extremely useful in the detection and monitoring of structural pathological changes (9). Recent studies have highlighted the close relationship between bone alterations and bone markers (10, 11). Cytokine dysregulation in SpA has been associated with the development of pathological bone alterations (12), suggesting that, in the future, the appropriate drug choice might be guided by the main cytokine axis involved (10, 13). However, it is currently not known how to assess and interpret the cytokine profile in clinical practice. On the other hand, imaging can already help in defining a precision medicine approach.
This review aims to discuss the role of imaging in the diagnosis, management, and prognosis of PsA over the last 5 years, including fundamental papers from inception to 2020. We used the MEDLINE/PubMed, CINAHL, EMBASE, and Cochrane Library databases. In addition, we manually searched references from the retrieved articles and explored a number of related websites. It covers the axial and peripheral types of the disease, and the imaging techniques taken into account are MRI, US, CT, and XR as well as novel techniques of advanced imaging, such as high-resolution peripheral computed tomography (HRpQ-CT) and dual energy computed tomography (DECT). Figure 1 depicts an Achilles' tendon enthesitis assessed with different modalities.
Figure 1. Achilles' tendon enthesitis of the same patients with peripheral SpA as assessed by XR (A), MRI with T1 sequences (B1), MRI with contrast-enhanced sequences (B2), and PD US (C). The various imaging techniques differently emphasize the pathological changes related to the disease, i.e., mainly bone changes with XR and soft tissue changes with MRI and US. Only MRI (B2) can document subcortical osteitis/bone marrow edema. Abbreviations: MRI, magnetic resonance imaging; SpA, spondyloarthritis; US, ultrasonography.
XR
Regarding XR, several papers were published between 2016 and 2019, most of which are related to therapy response. XR maintains an important role in the study of SpA and PsA because it is the discriminant for radiographic and nonradiographic types of sacroiliitis, but also because it is very helpful in differential diagnosis with other diseases, such as osteitis condensans.
Among the studies on diagnosis and prognosis, the paper by Aydin et al. (4) is focused on the impact and outcomes of undiagnosed axial PsA. Starting from PsA patients in the Turkish National Registry, 1195 were recruited, 112 of which fulfilled the modified New York (NY) criteria, even if they had not received a formal diagnosis of the axial disease. This group of patients also showed a worse outcome on peripheral PsA with a higher number of tender and swollen joints, but similar patients reported outcomes.
Salaffi et al. (14) propose a novel score for the staging of structural damage using XR, named the Simplified Psoriatic Arthritis Radiographic Score (SPARS). The scoring system considers the combination of erosions, joint-space narrowing, and bone proliferation. The method is compared with the PsA Ratingen score (PARS) (15) and the modified Sharp/Van der Heijde score (16). Regarding convergent validity, SPARS shows a strong correlation with both of them, with r = 0.904 and 0.926 (p < 0.0001), respectively. SPARS is advantageous in that it is time saving and has a good agreement between readers.
Regarding treatment, Allar et al. (17) explore the radiographic change, its evolution, and the effects of transitioning from conventional DMARD (cDMARD) to biological DMARD (bDMARD). A relatively small cohort (N = 28) was retrospectively conducted. The cohort fulfilled the CASPAR criteria and belonged to the Bath longitudinal cohort. Data analysis considered three time points: at baseline, at first prescription of bDMARD, and 5 years after the start of tumor necrosis factor-α inhibitors (TNFi). From baseline to commencing bDMARD, the rate of erosion progression was 2.1 (IQR, 0.88–3.93). The study ran for 5 years after commencing the first bDMARD, and the rate of erosion changed to 0.0 (IQR = 0.00–0.81), suggesting a slowing down of the process due to this intervention.
A subanalysis of GO-REVEAL data by Kerschbaumer et al. (18) concludes that the responsiveness of a functional limitation decreases with increasing joint damage in a cohort of patients treated with golimumab, which were divided into two groups (remission and responders with previous functional impairment). The increase in the total modified Sharp/Van der Heijde score results was strongly associated with higher values of Health Assessment Questionnaire (HAQ), for both joint space narrowing and erosions, but the latter was less determinant for disability even though the comparison with the remission group showed a strong significance (p < 0.0001). Data from the FUTURE5 study (19) show a significant inhibition of the modified Sharp/Van der Heijde score at week 24 in any group, disregarding drug dosage. Similar data were published for FUTURE1 (20), with a rate of nonprogressors equal to 78% for naïve to TNFi patients and 65.5% for the group that previously experienced therapy with TNFi. Another subanalysis from the GO-VIBRANT study (21) highlights the inhibition of the progression in structural damage in a cohort of patients treated with intravenous golimumab 2 mg/kg. The PsA-modified Sharp/Van der Heijde score shows a p < 0.001 in every subanalysis, for example, regarding erosions and joint space narrowing, demographic data, baseline characteristics, and concomitant treatment. Data suggest the beneficial effects of golimumab not only for the progression, but also for the prevention of new joint erosion, with a rate of no new joint erosions of 74.3 vs. 54% in the placebo group (p < 0.001).
US
US is a safe, readily available, and inexpensive instrument to study articular and extra-articular pathologies in patients with rheumatic diseases. The increasing role of musculoskeletal US in the diagnosis and management of PsA is reflected by the 2015 EULAR recommendations on the use of imaging in SpA (22). However, the optimal use of this technique in the clinical management of PsA is still to be defined, and data in this regard are lacking. This section constitutes an attempt to resume the most relevant publications addressing this issue in the last 3 years.
As far as the diagnosis of PsA is concerned, a higher sensitivity of US in detecting synovitis compared to clinical examination has been reproducibly confirmed by several controlled studies in the past. However, the value of US in addition to clinical examination (compared to clinical examination alone) in making the diagnosis of PsA is yet to be assessed (23).
Recently, in a study on patients with PsA and diagnosed according to the CASPAR criteria, US was able to detect markedly more joints with synovial proliferation (108 out of 840 joints) compared to clinical examination (32 and 59 of 840 joints graded as swollen and tender, respectively). In addition, the authors argue that US offers the opportunity to discriminate arthritis from tenosynovitis and subcutaneous edema while physical examination cannot distinguish between these different features (24).
In the differential diagnosis of early PsA and seronegative RA, it might be useful to combine US and dermoscopy. Detection of at least one extra-synovial feature using hand US and dotted vessels using nailfold dermoscopy was shown to be significantly associated with early PsA (25).
US could also help to identify patients with psoriatic arthralgia, that is, psoriasis (PSO) associated with nonspecific joint symptoms, who may be at risk of developing PsA. These patients were shown to have US signs of tenosynovitis significantly more often than patients with PSO alone (26).
Similarly, the presence of soft tissue edema, one of the anatomical components of dactylitis in PsA, might not only be useful as a diagnostic element in order to differentiate PsA from RA but also serve as an indicator of the disease severity. A novel US definition, including a grayscale and power Doppler (PD) scoring system of soft tissue edema in PsA, was proposed recently (26).
Another noteworthy finding in a study by Najm et al. (27) shows a good correlation of the degree of PD in US-detected knee joint synovitis with histopathological inflammation. The only other study that previously attempted to show such an agreement between US and a histopathological gold standard failed (28).
In a prospective observational study of 228 patients with recent-onset arthritis of the hands, thickening of the flexor tendon pulleys was reported to be a sensitive (80%) albeit unspecific (71%) US sign of PsA, which may, thus, be helpful in the diagnostic process if considered alongside other criteria (29). The same thickening of the flexor tendon pulleys, interpreted as “Deep Koebner's” response to physical stress, was found significantly more often in patients with established PsA than in patients with PSO alone, rheumatoid arthritis, or healthy controls (30).
US of the nail unit has drawn a great deal of attention in recent years. Nail involvement is a hallmark of psoriatic disease and is known to be associated with the development of PsA (31). The loss of the trilaminar structure of the nail plate, involvement of the extensor tendon at the level of the distal interphalangeal joint, and increased vascularization are the main features of psoriatic onychopathy. However, hypervascularization of the nail bed may also be present in healthy subjects (32). Similarly, thickening of the nail plate is also described in patients with osteoarthritis, whereas PD signal at entheseal levels seems to be quite specific for PsA. Overall, these US-described alterations of the nail unit are reported with a highly variable prevalence in the literature (33). Hence, despite promising clues, further research and standardization of the technique are required in order to reliably use nail US for diagnosis, prognosis, and monitoring of PsA.
US may also serve as an instrument to monitor disease activity and/or response to therapy.
A longitudinal study by Pukšić et al. (34) shows only poor a correlation between disease remission determined by the Disease Activity for Psoriatic Arthritis (DAPSA) score and PD US, indicating that the two measures depict different aspects of the disease. Accordingly, objective markers of inflammation, such as the 66 swollen joint count, CRP, and ESR, showed longitudinal agreement with PD US, whereas no correlation was observed for the pain-related components of DAPSA as well as patient-reported outcome measures (PROMs).
Similarly, pain and pain-related items were the main reasons why PsA patients with the absence of US signs of inflammation were classified with higher disease activity in another study comparing clinical and US definitions of low disease activity (LDA) (35). Both studies suggest that US may be helpful in objectively assessing residual inflammation, especially in patients with high, pain-driven, clinical scores but low clinical evidence of inflammation.
A study investigating PsA patients under IL-17 inhibition with secukinumab showed a significant decrease in PD US signs of joint inflammation after 24 weeks of treatment in good agreement with equally significant changes in MRI-detected synovitis as well as clinical measures of joint diseases such as DAPSA and DAS28-ESR (36).
In a longitudinal study on patients with clinically inactive juvenile idiopathic arthritis, US joint abnormalities, such as synovial hyperplasia, joint effusion, and PD signal, were shown to be strong predictors of the individual relapse risk (37).
In general, despite increasing data on the optimal integration of US into clinical practice, some areas remain controversial and/or fragmentary, particularly when it comes to the identification of US findings with potential prognostic value. Important answers in this regard are expected from future studies.
A brief summary of the main studies is reported in Table 1.
Table 1. Revised articles about US.
MRI in Peripheral Arthritis
MRI is a useful and sensitive tool to investigate the anatomical structures involved in peripheral arthritides. The 2015 EULAR recommendations for the use of imaging in SpA considers MRI as a valuable tool for supporting the diagnosis and monitoring disease activity and structural damage in peripheral SpA (pSpA) (22). However, the available data are still relatively scarce, and much of our knowledge is derived from studies on RA.
Typical MRI findings in peripheral PsA include synovitis, tenosynovitis, periarticular inflammation, bone edema, erosions, and bone proliferation (53). All these features have been included in a scoring system (PsAMRIS) (53), which was validated in 2015 with good intrareader agreement and sensitivity to change (54). Currently, MRI is still the only validated tool for the joint assessment of PsA (55). In addition, very recently, OMERACT has proposed the definitions for a bone and soft-tissue-based scoring system for enthesitis using the heel as a model (HEMRIS) (56) with good reliability values.
As is known, MRI scanning protocols for the assessment of peripheral PsA do not differ significantly from RA protocols and recommend the adoption of coronal and sagittal T1- and T2-weighted images with fat suppression or STIR/TIRM (53, 57). Acquisition of additional T1-weighted sequences after intravenous gadolinium-containing contrast agent is needed for optimal assessment of synovitis, osteitis, and tenosynovitis (53, 57) because fat-suppressed sequences alone may not be able to discriminate between joint fluid and an inflamed (and, therefore, highly vascularized) synovium.
As already discussed, enthesitis is one of the hallmarks of PsA, and MRI has been shown to be sensitive in detecting structural changes of this kind (58). Narváez et al. (59) investigate the usefulness of MRI as a complementary approach for differential diagnosis in ambiguous cases in a cohort of 20 patients with early RA and 17 with early PsA. No significant differences were found in joint synovitis, and tenosynovitis of the flexor tendons appeared to be more often present in PsA (70.6 vs. 30%, p = 0.014, with a sensitivity and specificity for PsA of 71 and 70%, respectively) and tenosynovitis of the extensors (at the wrist) in RA (70 vs. 29.6%, p = 0.014, with a sensitivity and specificity of 70 and 75%, respectively). Interestingly, the best values of specificity for PsA (100%) were observed for the findings of enthesitis and diaphyseal bone edema. In addition, soft tissue edema was a highly specific finding for PsA (95% specificity). Indeed, extracapsular involvement has often been observed in other small studies (60–62). Overall, an imbalance in the prevalence of this feature between PsA and RA has been consistently shown, yet the data are currently insufficient to recommend the adoption of these features as a criterion for differential diagnosis in clinical practice.
In 2019, the results of a sub-study of the TICOPA trial were published (41). The study evaluated the performance of noncontrast MRI (single hand, assessed by PsAMRIS) with an additional global inflammation score. US (same hand) was also performed. Good interobserver reliability was confirmed for all the features analyzed (synovitis, flexor tenosynovitis, periarticular inflammation, bone erosion, and bone edema) except for bone proliferation, which showed poor measures or inter-observer intra-class correlation. Overall, both the PsAMRIS and US inflammation scores demonstrated good responsiveness, and a good correlation between baseline and change scores for MRI and US was found as well as a good correlation between baseline MRI imaging and clinical scores. The authors also concluded that, despite the limitations of the study (i.e., low-field, single-region examination), the results showed a good sensitivity to change and, therefore, supported the construct validity of the change scores.
The finding of low inter-reliability values for bone proliferation is not unexpected. Pathological bone proliferation is typical of spondyloarthropathies and PsA (13, 36) although it is not a common finding in RA. Given that much of our knowledge on structural damage as well as the tools adopted for its assessment have been readapted from RA, anabolic changes represent a relatively new feature to investigate. However, interest is growing, and MRI offers intriguing insights on the matter. In the PsARTROS study (36), an open-label single group study on 20 patients affected by PsA and receiving treatment with secukinumab for 24 weeks, PsAMRIS score (along with other imaging techniques) of the hands was performed to assess synovitis, periarticular inflammation, bone erosion, and enthesophyte formation. Even in this relatively small sample, MRI proved to be effective in showing therapeutic response in terms of synovitis. Periarticular inflammation, which, in part, resembles enthesitis, completely resolved upon secukinumab treatment. In addition, both MRI and HRpQ-CT showed the absence of the development of both erosive and bone anabolic damage, supporting the possibility of the arrest of progression of anabolic changes in PsA with secukinumab.
Another relevant field of research is the characterization of subclinical joint and tendon involvement in patients diagnosed with cutaneous PSO. In 1998, Offidani et al. (63) observed that, in a cohort of 25 patients free of joint symptoms, 68% of them were positive for one or more arthritic signs on MRI with soft-tissue abnormalities being the most prevalent (44%). Similar observations have been repeatedly published in the literature (64–67) with quite a heterogeneous prevalence depending on the sites investigated and the described lesions. Overall, the current evidence seems to suggest that more than half of the otherwise asymptomatic subjects affected by PSO show a subclinical inflammatory involvement. On this account, the data from a prospective single-arm open-label study on 20 patients with PSO without an established diagnosis of PsA treated with secukinumab (an anti-interleukin-17 monoclonal antibody) have been recently published. The cohort concerned patients at high risk for developing overt arthritic involvement (85% of them reported arthralgia, and 40% had tender joints at baseline examination, and 83% had at least one inflammatory lesion on MRI). The extent of arthralgia significantly declined after 24 weeks of secukinumab treatment, and a significant improvement in patient-reported outcomes and quality of life was observed. In addition, the sequential assessment of joint inflammation by MRI showed a significant decrease in global PsAMRIS and PsAMRIS synovitis scores. The possibility of identifying patients in a prodromal phase for the development of symptomatic joint involvement and to successfully intervene with a specific treatment is intriguing. In particular, we consider the benefits of an early treat-to-target approach in PsA (68).
MRI and Axial Involvement
As was the case in peripheral PsA, in axial PsA (ax-PsA), most of our imaging knowledge is derived from a wider population. In this case, it is carried out from studies involving patients affected by SpA, and only a little research has been conducted specifically on ax-PsA. This strategy, unavoidable in a setting characterized by the scarcity of data, is affected by some limitations. Indeed, it is known that although the inflammatory ax-PsA can be indistinguishable from other forms of axial SpA, such as ankylosing spondylitis (AS), it can also differ from it in several respects: Overall, the available literature seems to suggest clinically, radiographically, and prognostically worse axial disease in patients with AS than in patients with ax-PsA (7).
Nevertheless, MRI acquisition protocols and definitions for active and structural lesions are also generally used for ax-PsA (69).
In particular, the correlation between the clinical diagnosis of inflammatory back pain and its relative MRI findings is one of the most important topics to clarify. Monaldo-Ficco et al. (70) report, in a cohort of 125 patients (including both peripheral and/or ax-PsA), that, in less than half of the subjects with a clinical diagnosis of inflammatory back pain, structural and/or inflammatory lesions were observed, and ~30% had degenerative changes. On the other hand, of the 46 patients with mechanical back pain, 20% had changes consistent with spondylitis, whereas 72% had only degenerative changes. The authors conclude that inflammatory back pain might result from mechanisms other than inflammation. In addition, we should also suspect that symptoms of ax-PsA might not present as classical inflammatory low back pain in a nonnegligible proportion of patients.
Given the somewhat unpredictable distribution of peripheral, axial, and soft-tissue involvement in PsA, whole-body MRI has been investigated and has been shown to allow effective simultaneous assessment of peripheral and axial joints in PsA (71). However, this head-to-toe technique is affected by practical limitations and requires further testing before its consideration for a wider setting.
A brief summary of the main studies is reported in Table 2, divided according to the different types.
Table 2. Revised articles about MRI, split for peripheral, or axial subset of disease.
Novel Techniques
Bone lesions can be divided into erosive or secondary to new bone formation. HRpQ-CT is a novel and promising technique that allows for the study of both, and it is mainly used in the diagnosis and evaluation of the disease progression (72–74). Simon et al. (74) evaluate the joints of 203 individuals affected by PSO, PsA, or healthy subjects. The presence of erosions in the PsA group was higher than in the control groups (140 erosions found vs. 27 in PSO group or in healthy controls; p = 0.002 for both comparisons). The volume of erosions was also significant with greater values in patients affected by PsA vs. PSO and healthy controls (p = 0.003 and 0.004, respectively). Nonsubstantial differences were found between PSO and healthy controls, and the conclusions of the authors are about a higher grade of involvement in PsA than in PSO or healthy status. This is due to an inflammatory trigger, which could lead to a heavier burden of the disease.
A similar work by Henchie et al. (75) tries to outline an image-based method for measuring joint deformities, considering erosions or bone growth. The algorithm is predictive and attempts to elaborate the prior healthy bone surface in a probabilistic manner. The authors considered the second metacarpal phalangeal joint of patients affected by PsA or RA. The algorithm was tested with computed models and surfaces altered by artificial erosions and bone growth in order to define the sensibility and specificity of the reconstructed model. For both PsA and RA, the number of lesions (erosions) was higher than that of the control group composed of healthy subjects. Even if the authors stated limitations of the algorithm, the method is still able to discriminate the volume and number of erosions, confirming the data already present in the literature. In addition, its development might lead to the creation of a valuable tool for the diagnosis and reconstruction surgery of the hand.
Only one study from Kampylafka et al. (36) reports data on HRpQ-CT variations before and after therapy. In patients treated with secukinumab, no progression is shown for enthesophytes or erosions after 24 weeks [erosions: median at baseline 2 (IQR = 0.5–4.5) and 2 (IQR = 1–4) after 24 weeks; entesophytes from 2 (IQR = 1–2) to 2 (IQR = 1.5–2)].
Another novel technique is DECT. It allows the acquisition of two different sets of images using different X-ray levels of energy. Two papers from Fukuda et al. (76, 77) were published in 2017 and focused on the diagnostic advantages of the technique. The first paper is about a prospective study that evaluated 16 patients, scoring the damage using the PsA MRI scoring system (PsAMRIS) (54) and comparing DECT with MRI. The sensitivity and specificity were 78 and 87%, respectively. The agreement with MRI was 86.3%. The authors found that DECT more often detects inflammatory lesions of the distal interphalangeal joints (DIP) or proximal interphalangeal joints (PIP). More in general, according to the authors, DECT supports inflammatory findings more often than MRI, but it is not found in metacarpal phalangeal joints (MCP) because this region is more extended in comparison with DIP and PIP. MRI is less limited in studying the surface area covered by DECT. The second paper speculates on the potential usefulness of DECT using iodine mapping for the study of peripheral arthritis. The comparison of synovitis highlights differences between RA and PsA with a prominent presence of inflammatory lesions in extra-articular structures, such as pulleys. The technique also seems to be useful in studying typical features, such as paratenonitis and ligaments. This study by Fukuda et al. (77) suggests that DECT iodine mapping could be a reliable technique that combines many advantages for diagnosis, assessment of damage, and drug response.
One final promising technique is fluorescence optical imaging (FOI). FOI is based on light-emitting diodes in the near-infrared spectrum that excite the fluorescence of an intravenously applied dye indocyanine green (ICG), which is used as contrast enhancer (78). In this manner, it can detect pathologic vascular changes, especially in areas such as the nail-enthesis complex.
Currently, there are only few studies investigating FOI in PsA. In 2019, Wiemann et al. (78) analyzed the characteristics of FOI signals in a cohort of PsA patients and found one particular pattern (“green nail”) to be highly specific (97%) for PsA.
Another study investigated the role of FOI in the early diagnosis of PsA in a smaller group of patients with certain vs. uncertain PsA and compared FOI with US (79). FOI seemed to be slightly more sensitive than US in detecting very early signs of PsA with the advantage of a comprehensive overview of the hand's structures. The main technical limitations are the need of ICG, that needs to be intravenously administrated and, at the current state of development, the fact that only hands and wrists can be examined.
Conclusions
Imaging is becoming more important with time. It is probably the best “clinical biomarker” for spondyloarthritis because laboratory tests are poor in specificity and not satisfactory in detailing disease activity. In past decades, the canonical division between conventional (standing for XR) and advanced (US and MRI) has been widely adopted. Currently, this classification is no longer valid. The so-called advanced techniques became more available; thus, the old distinction is now based on several peculiarities of the imaging tool used. XR remains the standard for the therapy response and is a signature mark for every study that takes into account outcomes of disease progression. US and MRI are very useful for assessing early signs of PsA activity with a comprehensive evaluation of almost all structures involved. Promising data, especially in the field of CT, are now emerging (Table 3). The opportunity to obtain data for both anatomical and functional evaluation makes DECT very promising in this field. Furthermore, a novel approach to PsA damage might be given by HRpQ-CT because new bone formation and erosions are clearly seen even in the very early stage of the disease.
Table 3. Features and perspectives of the different imaging techniques in PsA.
Author Contributions
All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.
Conflict of Interest
AF reports personal fees from Abiogen, Novartis, Neopharmed, outside the submitted work. LI reports personal fees from Eli-Lilly, Merck Sharp and Dohme, Novartis, Sanofi, Celgene, UCB outside the submitted work.
The remaining author declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
2. Kaeley GS, Eder L, Aydin SZ, Gutierrez M, Bakewell C. Enthesitis: A hallmark of psoriatic arthritis. Semin Arthritis Rheum. (2018) 48:35–43. doi: 10.1016/j.semarthrit.2017.12.008
3. Kaeley GS, Eder L, Aydin SZ, Gutierrez M, Bakewell C. Dactylitis: A hallmark of psoriatic arthritis. Semin Arthritis Rheum. (2018) 48:263–73. doi: 10.1016/j.semarthrit.2018.02.002
4. Aydin SZ, Kucuksahin O, Kilic L, Dogru A, Bayindir O, Ozisler C, et al. Axial psoriatic arthritis: the impact of underdiagnosed disease on outcomes in real life. Clin Rheumatol. (2018) 37:3443–8. doi: 10.1007/s10067-018-4173-4
5. Danve A, Deodhar A. Axial spondyloarthritis in the USA: diagnostic challenges and missed opportunities. Clin Rheumatol. (2019) 38:625–34. doi: 10.1007/s10067-018-4397-3
6. Jadon DR, Sengupta R, Nightingale A, Lindsay M, Korendowych E, Robinson G, et al. Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann Rheum Dis. (2017) 76:701–7. doi: 10.1136/annrheumdis-2016-209853
7. Feld J, Chandran V, Haroon N, Inman R, Gladman D. Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. Nat Rev Rheumatol. (2018) 14:363–71. doi: 10.1038/s41584-018-0006-8
8. Paine A, Ritchlin C. Altered bone remodeling in psoriatic disease: new insights and future directions. Calcif Tissue Int. (2018) 102:559–74. doi: 10.1007/s00223-017-0380-2
9. Mathew AJ, Coates LC, Danda D, Conaghan PG. Psoriatic arthritis: lessons from imaging studies and implications for therapy. Expert Rev Clin Immunol. (2017) 13:133–42. doi: 10.1080/1744666X.2016.1215245
10. Fassio A, Gatti D, Rossini M, Idolazzi L, Giollo A, Adami G, et al. Secukinumab produces a quick increase in WNT signalling antagonists in patients with psoriatic arthritis. Clin Exp Rheumatol. (2018) 133-136.
11. Fassio A, Idolazzi L, Viapiana O, Benini C, Vantaggiato E, Bertoldo F, et al. In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls. Clin Rheumatol. (2017) 36:2377–81. doi: 10.1007/s10067-017-3734-2
12. Belasco J, Wei N. Psoriatic arthritis: what is happening at the joint? Rheumatol Ther. (2019) 6:305–15. doi: 10.1007/s40744-019-0159-1
13. Fassio A, Rossini M, Viapiana O, Idolazzi L, Benini C, Vantaggiato E, et al. New strategies for the prevention and treatment of systemic and local bone loss; from pathophysiology to clinical application. Curr Pharm Des. (2017) 23:6241–50. doi: 10.2174/1381612823666170713104431
14. Salaffi F, Carotti M, Di Donato E, Di Carlo M, Luchetti MM, Ceccarelli L, et al. Preliminary validation of the simplified psoriatic arthritis radiographic score (SPARS). Skeletal Radiol. (2019) 48:1033–41. doi: 10.1007/s00256-018-3124-0
15. Wassenberg S. Radiographic scoring methods in psoriatic arthritis. Clin Exp Rheumatol. (2015) 33:S55–9.
16. van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van 't Hof MA, van Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum. (1992) 35:26–34. doi: 10.1002/art.1780350105
17. Allard A, Antony A, Shaddick G, Jadon DR, Cavill C, Robinson G, et al. Trajectory of radiographic change over a decade: the effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis. Rheumatol Oxf Engl. (2019) 58:269–73. doi: 10.1093/rheumatology/key297
18. Kerschbaumer A, Baker D, Smolen JS, Aletaha D. The effects of structural damage on functional disability in psoriatic arthritis. Ann Rheum Dis. (2017) 76:2038–45. doi: 10.1136/annrheumdis-2017-211433
19. Mease P, van der Heijde D, Landewé R, Mpofu S, Rahman P, Tahir H, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. (2018) 77:890–7. doi: 10.1136/annrheumdis-2017-212687
20. Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, et al. Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD Open. (2018) 4:e000723. doi: 10.1136/rmdopen-2018-000723
21. Kavanaugh A, van der Heijde D, Beutler A, Gladman D, Mease P, Krueger GG, et al. Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study. Arthritis Care Res. (2016) 68:267–74. doi: 10.1002/acr.22576
22. Mandl P, Navarro-Compán V, Terslev L, Aegerter P, van der Heijde D, D'Agostino MA, et al. EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Ann Rheum Dis. (2015) 74:1327–39. doi: 10.1136/annrheumdis-2014-206971
23. Zabotti A, Idolazzi L, Batticciotto A, De Lucia O, Scirè CA, Tinazzi I, et al. Enthesitis of the hands in psoriatic arthritis: an ultrasonographic perspective. Med Ultrason. (2017) 19:438–43. doi: 10.11152/mu-1172
24. Florescu A, Muşetescu AE, Florescu LM, Bondari A, Ciurea PL, Vere CC, et al. The role of ultrasound in assessing hand joints and tendons in psoriatic arthritis. Curr Health Sci J. (2019) 45:198–203. doi: 10.12865/CHSJ.45.02.11
25. Zabotti A, Piga M, Canzoni M, Sakellariou G, Iagnocco A, Scirè CA, UPSTREAM study group. Ultrasonography in psoriatic arthritis: which sites should we scan? Ann Rheum Dis. (2018) 77:1537–8. doi: 10.1136/annrheumdis-2018-213025
26. Zabotti A, McGonagle DG, Giovannini I, Errichetti E, Zuliani F, Zanetti A, et al. Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia. RMD Open. (2019) 5:e001067. doi: 10.1136/rmdopen-2019-001067
27. Najm A, Orr C, Gallagher L, Biniecka M, Gaigneux E, Le Goff B, et al. Knee joint synovitis: study of correlations and diagnostic performances of ultrasonography compared with histopathology. RMD Open. (2018) 4:e000616. doi: 10.1136/rmdopen-2017-000616
28. Koski JM, Saarakkala S, Helle M, Hakulinen U, Heikkinen JO, Hermunen H. Power Doppler ultrasonography and synovitis: correlating ultrasound imaging with histopathological findings and evaluating the performance of ultrasound equipments. Ann Rheum Dis. (2006) 65:1590–1595. doi: 10.1136/ard.2005.051235
29. Furlan A, Stramare R. The thickening of flexor tendons pulleys: a useful ultrasonographical sign in the diagnosis of psoriatic arthritis. J Ultrasound. (2018) 21:309–14. doi: 10.1007/s40477-018-0325-2
30. Tinazzi I, McGonagle D, Aydin SZ, Chessa D, Marchetta A, Macchioni P. “Deep Koebner” phenomenon of the flexor tendon-associated accessory pulleys as a novel factor in tenosynovitis and dactylitis in psoriatic arthritis. Ann Rheum Dis. (2018) 77:922–5. doi: 10.1136/annrheumdis-2017-212681
31. Ash ZR, Tinazzi I, Gallego CC, Kwok C, Wilson C, Goodfield M, et al. Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. Ann Rheum Dis. (2012) 71:553–6. doi: 10.1136/annrheumdis-2011-200478
32. Aydin SZ, Castillo-Gallego C, Ash ZR, Marzo-Ortega H, Wakefield R, McGonagle D. Vascularity of nail bed by ultrasound to discriminate psoriasis, psoriatic arthritis and healthy controls. Clin Exp Rheumatol. (2017) 35:872.
33. Fassio A, Giovannini I, Idolazzi L, Zabotti A, Iagnocco A, Sakellariou G. Nail ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review. Clin Rheumatol. (2020) 39:1391–404. doi: 10.1007/s10067-019-04748-2
34. Pukšić S, Bolton-King P, Sexton J, Michelsen B, Kvien TK, Berner Hammer H. DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs. RMD Open. (2018) 4:e000765. doi: 10.1136/rmdopen-2018-000765
35. Bosch P, Husic R, Ficjan A, Gretler J, Lackner A, Graninger WB, et al. Evaluating current definitions of low disease activity in psoriatic arthritis using ultrasound. Rheumatol Oxf Engl. (2019) 58:2212–20. doi: 10.1093/rheumatology/kez237
36. Kampylafka E, d'Oliveira I, Linz C, Lerchen V, Stemmler F, Simon D, et al. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study. Arthritis Res Ther. (2018) 20:153. doi: 10.1186/s13075-018-1653-5
37. De Lucia O, Ravagnani V, Pregnolato F, Hila A, Pontikaki I, Gattinara M, et al. Baseline ultrasound examination as possible predictor of relapse in patients affected by juvenile idiopathic arthritis (JIA). Ann Rheum Dis. (2018) 77:1426–431. doi: 10.1136/annrheumdis-2017-211696
38. Idolazzi L, Zabotti A, Fassio A, Errichetti E, Benini C, Vantaggiato E, et al. The ultrasonographic study of the nail reveals differences in patients affected by inflammatory and degenerative conditions. Clin Rheumatol. (2019) 38:913–20. doi: 10.1007/s10067-019-04437-0
39. Tinazzi I, McGonagle D, Macchioni P, Aydin SZ. Power Doppler enhancement of accessory pulleys confirming disease localization in psoriatic dactylitis. Rheumatol Oxf Engl. (2020) 59:2030–4. doi: 10.1093/rheumatology/kez549
40. Tang Y, Cheng S, Yang Y, Xiang X, Wang L, Zhang L, et al. Ultrasound assessment in psoriatic arthritis (PsA) and psoriasis vulgaris (non-PsA): which sites are most commonly involved and what features are more important in PsA? Quant Imaging Med Surg. (2020) 10:86–95. doi: 10.21037/qims.2019.08.09
41. Helliwell PS, Coates LC, Chew NS, Lettieri G, Moverley AR, Freeston JE, et al. Comparing psoriatic arthritis low-field magnetic resonance imaging, ultrasound and clinical outcomes: data from the TICOPA trial. J Rheumatol. (2019) doi: 10.3899/jrheum.181385
42. Krajewska-Włodarczyk M, Owczarczyk-Saczonek A, Placek W, Wojtkiewicz M, Wiktorowicz A, Wojtkiewicz J, et al. Ultrasound assessment of changes in nails in psoriasis and psoriatic arthritis. BioMed Res Int. (2018) 2018:8251097. doi: 10.1155/2018/8251097
43. Mondal S, Dutta S, Lahiri D, Sinha D, Sircar G, Mandal AK, et al. Assessment of nail unit structures by ultrasound in patients with psoriatic arthritis and their correlations with disease activity indices: a case-control study. Rheumatol Int. (2018) 38:2087–93. doi: 10.1007/s00296-018-4160-8
44. Macía-Villa C, Falcao S, Gutierrez M, Medina J, Hammer HB, De Miguel E. What is metacarpophalangeal joint swelling in psoriatic arthritis? Ultrasound findings and reliability assessment. Clin Exp Rheumatol. (2018) 36:896–9.
45. Højgaard P, Ellegaard K, Nielsen SM, Christensen R, Guldberg-Møller J, Ballegaard C, et al. Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: a prospective cohort study. Arthritis Care Res. (2019) 71:798–810. doi: 10.1002/acr.23693
46. Idolazzi L, Gisondi P, Fassio A, Viapiana O, Giollo A, Rossini M, et al. Ultrasonography of the nail unit reveals quantitative and qualitative alterations in patients with psoriasis and psoriatic arthritis. Med Ultrason. (2018) 20:177–84. doi: 10.11152/mu-1327
47. Ahmed MM, Elolemy GG, Alfeeli AK, Baqer AB, Gad AM. Ultrasonographic enthesopathy and disease activity in psoriatic arthritis. Open Access Maced J Med Sci. (2017) 5:651–6. doi: 10.3889/oamjms.2017.070
48. Uson J, Loza E, Möller I, Acebes C, Andreu JL, Batlle E, et al. Recommendations for the use of ultrasound and magnetic resonance in patients with spondyloarthritis, including psoriatic arthritis, and patients with juvenile idiopathic arthritis. Reumatol Clin. (2018) 14:27–35. doi: 10.1016/j.reuma.2016.08.008
49. Fiocco U, Stramare R, Martini V, Coran A, Caso F, Costa L, Felicetti M, Rizzo G, Tonietto M, Scanu A, et al. Quantitative imaging by pixel-based contrast-enhanced ultrasound reveals a linear relationship between synovial vascular perfusion and the recruitment of pathogenic IL-17A-F+IL-23+ CD161+ CD4+ T helper cells in psoriatic arthritis joints. Clin Rheumatol. (2017) 36:391–9. doi: 10.1007/s10067-016-3500-x
50. Ceccarelli F, Lucchetti R, Perricone C, Spinelli FR, Cipriano E, Truglia S, et al. Musculoskeletal ultrasound in monitoring response to apremilast in psoriatic arthritis patients: results from a longitudinal study. Clin Rheumatol. (2019) 38:3145–51. doi: 10.1007/s10067-019-04674-3
51. Alivernini S, Tolusso B, Petricca L, Bui L, Di Sante G, Peluso G, et al. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission? Ann Rheum Dis. (2017) 76:1228–36. doi: 10.1136/annrheumdis-2016-210424
52. Ramírez J, Inciarte-Mundo J, Cuervo A, Ruiz-Esquide V, Hernández MV, Sanmartí R, et al. Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission. Clin Exp Rheumatol. (2017) 35:74–9.
53. Ostergaard M, McQueen F, Wiell C, Bird P, Bøyesen P, Ejbjerg B, et al. The OMERACT psoriatic arthritis magnetic resonance imaging scoring system (PsAMRIS): definitions of key pathologies, suggested MRI sequences, and preliminary scoring system for PsA Hands. J Rheumatol. (2009) 36:1816–24. doi: 10.3899/jrheum.090352
54. Glinatsi D, Bird P, Gandjbakhch F, Mease PJ, Bøyesen P, Peterfy CG, et al. Validation of the OMERACT psoriatic arthritis magnetic resonance imaging score (PsAMRIS) for the hand and foot in a randomized placebo-controlled trial. J Rheumatol. (2015) 42:2473–9. doi: 10.3899/jrheum.141010
55. Eder L, Aydin SZ, Kaeley GS, Maksymowych WP, Østergaard M. Options for assessing joints and entheses in psoriatic arthritis by ultrasonography and magnetic resonance imaging: how to move forward. J Rheumatol Suppl. (2018) 94:44–7. doi: 10.3899/jrheum.180140
56. Mathew AJ, Krabbe S, Eshed I, Gandjbakhch F, Bird P, Pedersen SJ, et al. The OMERACT MRI in enthesitis initiative: definitions of key pathologies, suggested MRI sequences, and a novel heel enthesitis scoring system. J Rheumatol. (2019) 46:1232–8. doi: 10.3899/jrheum.181093
57. Sudoł-Szopińska I, Jurik AG, Eshed I, Lennart J, Grainger A, Østergaard M, Klauser A, et al. Recommendations of the ESSR arthritis subcommittee for the use of magnetic resonance imaging in musculoskeletal rheumatic diseases. Semin Musculoskelet Radiol. (2015) 19:396–411. doi: 10.1055/s-0035-1564696
58. Feydy A, Lavie-Brion M-C, Gossec L, Lavie F, Guerini H, Nguyen C, et al. Comparative study of MRI and power Doppler ultrasonography of the heel in patients with spondyloarthritis with and without heel pain and in controls. Ann Rheum Dis. (2012) 71:498–503. doi: 10.1136/annrheumdis-2011-200336
59. Narváez J, Narváez JA, de Albert M, Gómez-Vaquero C, Nolla JM. Can magnetic resonance imaging of the hand and wrist differentiate between rheumatoid arthritis and psoriatic arthritis in the early stages of the disease? Semin Arthritis Rheum. (2012) 42:234–45. doi: 10.1016/j.semarthrit.2012.03.016
60. Jevtic V, Watt I, Rozman B, Kos-Golja M, Demsar F, Jarh O. Distinctive radiological features of small hand joints in rheumatoid arthritis and seronegative spondyloarthritis demonstrated by contrast-enhanced (Gd-DTPA) magnetic resonance imaging. Skeletal Radiol. (1995) 24:351–5. doi: 10.1007/BF00197064
61. Marzo-Ortega H, Tanner SF, Rhodes LA, Tan AL, Conaghan PG, Hensor EMA, et al. Magnetic resonance imaging in the assessment of metacarpophalangeal joint disease in early psoriatic and rheumatoid arthritis. Scand J Rheumatol. (2009) 38:79–83. doi: 10.1080/03009740802448833
62. Schoellnast H, Deutschmann HA, Hermann J, Schaffler GJ, Reittner P, Kammerhuber F, et al. Psoriatic arthritis and rheumatoid arthritis: findings in contrast-enhanced MRI. AJR Am J Roentgenol. (2006) 187:351–7. doi: 10.2214/AJR.04.1798
63. Offidani A, Cellini A, Valeri G, Giovagnoni A. Subclinical joint involvement in psoriasis: magnetic resonance imaging and X-ray findings. Acta Derm Venereol. (1998) 78:463–5. doi: 10.1080/000155598442809
64. Erdem CZ, Tekin NS, Sarikaya S, Erdem LO, Gulec S. MR imaging features of foot involvement in patients with psoriasis. Eur J Radiol. (2008) 67:521–5. doi: 10.1016/j.ejrad.2007.08.005
65. Emad Y, Ragab Y, Bassyouni I, Moawayh O, Fawzy M, Saad A, et al. Enthesitis and related changes in the knees in seronegative spondyloarthropathies and skin psoriasis: magnetic resonance imaging case-control study. J Rheumatol. (2010) 37:1709–17. doi: 10.3899/jrheum.100068
66. Mathew AJ, Bird P, Gupta A, George R, Danda D. Magnetic resonance imaging (MRI) of feet demonstrates subclinical inflammatory joint disease in cutaneous psoriasis patients without clinical arthritis. Clin Rheumatol. (2018) 37:383–8. doi: 10.1007/s10067-017-3895-z
67. Faustini F, Simon D, Oliveira I, Kleyer A, Haschka J, Englbrecht M, et al. Subclinical joint inflammation in patients with psoriasis without concomitant psoriatic arthritis: a cross-sectional and longitudinal analysis. Ann Rheum Dis. (2016) 75:2068–74. doi: 10.1136/annrheumdis-2015-208821
68. Dures E, Shepperd S, Mukherjee S, Robson J, Vlaev I, Walsh N, et al. Treat-to-target in PsA: methods and necessity. RMD Open. (2020) 6:e001083. doi: 10.1136/rmdopen-2019-001083
69. Maksymowych WP, Lambert RG, Østergaard M, Pedersen SJ, Machado PM, Weber U, Bennett AN, et al. MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. Ann Rheum Dis. (2019) 78:1550–8. doi: 10.1136/annrheumdis-2019-215589
70. Maldonado-Ficco H, Sheane BJ, Thavaneswaran A, Chandran V, Gladman DD. Magnetic resonance imaging in psoriatic arthritis: a descriptive study of indications, features and effect on treatment change. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. (2017) 23:243–5. doi: 10.1097/RHU.0000000000000558
71. Poggenborg RP, Pedersen SJ, Eshed I, Sørensen IJ, Møller JM, Madsen OR. Head-to-toe whole-body MRI in psoriatic arthritis, axial spondyloarthritis and healthy subjects: first steps towards global inflammation and damage scores of peripheral and axial joints. Rheumatol Oxf Engl. (2015) 54:1039–49. doi: 10.1093/rheumatology/keu439
72. Stach CM, Bäuerle M, Englbrecht M, Kronke G, Engelke K, Manger B, et al. Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography. Arthritis Rheum. (2010) 62:330–9. doi: 10.1002/art.27252
73. Finzel S, Englbrecht M, Engelke K, Stach C, Schett G. A comparative study of periarticular bone lesions in rheumatoid arthritis and psoriatic arthritis. Ann Rheum Dis. (2011) 70:122–7. doi: 10.1136/ard.2010.132423
74. Simon D, Kleyer A, Faustini F, Englbrecht M, Haschka J, Berlin A, et al. Simultaneous quantification of bone erosions and enthesiophytes in the joints of patients with psoriasis or psoriatic arthritis - effects of age and disease duration. Arthritis Res Ther. (2018) 20:203. doi: 10.1186/s13075-018-1691-z
75. Henchie TF, Gravallese EM, Bredbenner TL, Troy KL. An image-based method to measure joint deformity in inflammatory arthritis: development and pilot study. Comput Methods Biomech Biomed Engin. (2019) 22:942–952. doi: 10.1080/10255842.2019.1607315
76. Fukuda T, Umezawa Y, Tojo S, Yonenaga T, Asahina A, Nakagawa H, et al. initial experience of using dual-energy CT with an iodine overlay image for hand psoriatic arthritis: comparison study with contrast-enhanced MR imaging. Radiology. (2017) 284:134–42. doi: 10.1148/radiol.2016161671
77. Fukuda T, Umezawa Y, Asahina A, Nakagawa H, Furuya K, Fukuda K. Dual energy CT iodine map for delineating inflammation of inflammatory arthritis. Eur Radiol. (2017) 27:5034–5040. doi: 10.1007/s00330-017-4931-8
78. Wiemann O, Werner SG, Langer H-E, Backhaus M, Chatelain R. The “green nail” phenomenon in ICG-enhanced fluorescence optical imaging - a potential tool for the differential diagnosis of psoriatic arthritis. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. (2019) 17:138–47. doi: 10.1111/ddg.13747
79. Erdmann-Keding M, Ohrndorf S, Werner SG, Glimm A-M, Burmester G-R, Kokolakis G, et al. Fluorescence optical imaging for the detection of potential psoriatic arthritis in comparison to musculoskeletal ultrasound. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. (2019) 17:913–21. doi: 10.1111/ddg.13931
Keywords: psoriatic arthritis, psoriasis, biologics, magnetic resonace imaging (MRI), ultrasonography
Citation: Fassio A, Matzneller P and Idolazzi L (2020) Recent Advances in Imaging for Diagnosis, Monitoring, and Prognosis of Psoriatic Arthritis. Front. Med. 7:551684. doi: 10.3389/fmed.2020.551684
Received: 14 April 2020; Accepted: 07 September 2020;
Published: 29 October 2020.
Edited by:
Ying Ying Leung, Duke-NUS Medical School, SingaporeReviewed by:
Sarah Ohrndorf, Charité—Universitätsmedizin Berlin, GermanyMassimo De Martinis, University of L'Aquila, Italy
Copyright © 2020 Fassio, Matzneller and Idolazzi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Angelo Fassio, angelo.fassio@univr.it